Treatment Guidelines - Issue 115 | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

115

March 1, 2012

View Complete Issue Table of Contents 2019

Issue 115

Drugs for Inflammatory Bowel Disease

Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.

Drugs for Inflammatory Bowel Disease

March 1, 2012 (Issue: 115)

Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of Gastroenterology.

Show References Hide References

1. GR Lichtenstein et al. Management of Crohn’s disease in adults. Am J Gastroenterol 2009; 104:465.

2. A Kornbluth et al. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501.

3. C Campregher and C Gasche. Aminosalicylates. Best Pract Res Clin Gastroenterol 2011; 25:535.

4. Once-daily mesalamine (Lialda) for ulcerative colitis. Med Lett Drugs Ther 2007; 49:25.

5. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther 2009; 51:38.

6. P Marteau et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960.

7. AC Ford et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:617.

8. KJ Khan et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:661.

9. GT Ho et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24:319.

10. AH Steinhart et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003; (4): CD000301.

11. Budesonide (Entocort EC) for Crohn’s disease. Med Lett Drugs Ther 2002; 44:6.

12. AG Fraser et al. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50:485.

13. JF Colombel et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362:1383.

14. L Peyrin-Biroulet et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141:1621.

15. L Beaugerie et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617.

16. A Thai and T Prindiville. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn’s Colitis 2010; 4:511.

17. FDA drug safety communication: safety review update on reports of hepatosplenic T-cell lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine, and/or mercaptopurine. Available at http://www.fda.gov. Accessed February 7, 2012.

18. S Vermeire et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007; 56:1226.

19. BG Feagan et al. Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995; 332:292.

20. BG Feagan et al. Acomparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 2000; 342:1627.

21. S Lichtiger et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841.

22. M Naganuma et al. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 2011; 46:129.

23. H Ogata et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55:1255.

24. Certolizumab (Cimzia) for Crohn’s disease. Med Lett Drugs Ther 2008; 50:81.

25. D Tracey et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244.

26. GR Lichtenstein et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:935.

27. SR Targan et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337:1029.

28. SB Hanauer et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359:1541.

29. DH Present et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340:1398.

30. BE Sands et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350:876.

31. M Regueiro et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136:441.

32. JF Colombel et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132:52.

33. S Schreiber et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357:239.

34. L Peyrin-Biroulet et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6:644.

35. WJ Sandborn et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829.

36. S Danese et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn’s disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm Bowel Dis 2008; 14:1168.

37. P Rutgeerts et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462.

38. W Reinisch et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60:780.

39. WJ Sandborn et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257.

40. WJ Sandborn et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353:1912.

41. SR Targan et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology 2007; 132:1672.

42. Natalizumab (Tysabri) for Crohn's disease. Med Lett Drugs Ther 2008; 50:34.

43. US Food & Drug Administration. FDA News Release: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri. January 20, 2012. Available at: http://www.fda.gov. Accessed February 7, 2012.

44. Probiotics. Med Lett Drugs Ther 2007; 49:66.

45. JP Buts and N De Keyser. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006; 51:1485.

46. MH Floch and DC Montrose. Use of probiotics in humans: an analysis of the literature. Gastroenterol Clin North Am 2005; 34:547.

47. BJ Rembacken et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354:635.

48. W Kruis et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissile 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617.

49. MA Zocco et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23:1567.

50. P Gionchetti et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.